Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of SAR442168 vs placebo in nonrelapsing secondary progressive multiple sclerosis
2020-000647-30Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing SAR442168 with Placebo (2 arms). Primary endpoint: 6-month confirmed disability progression (CDP). Started Jun 2020; status: completed.
02
Drugs
tolebrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2020-000647-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000647-30.